AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
The company said in a news release that it modified the FreeStyle Libre 2 and the next-generation FreeStyle Libre 3. FreeStyle Libre 3 received FDA clearance in May 2022. The modifications allowed for the integrated CGMs to combine with AID systems, Abbott said.
BTIG analyst Marie Thibault maintained her “Buy” rating for Abbott after its “long-awaited win.”
Get the full story at our sister site, Drug Delivery Business News.